<DOC>
	<DOC>NCT00144976</DOC>
	<brief_summary>The purpose of this study is to evaluate the biological effect of Tarceva (OSI-774) from an inhibition of EGF tumor receptor tyrosine kinase activity's point of view, for patients who are carriers of head and neck epidermoid carcinoma.</brief_summary>
	<brief_title>Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma</brief_title>
	<detailed_description>Patients will receive Tarceva in continuous between 18 and 28 days after pan-endoscopy exam until surgery</detailed_description>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Neck and head epidermoid carcinoma histologically proved. Patient with an ENT epidermoid tumor can be included in the study if this relapse is located in an area not irradiated yet. At least tumor classified T2NXM0 Patient who can be picked up in a first surgery with a curative purpose or who must have a necessity's surgery (cervical curettage for voluminous adenopathies before radiotherapy) Patient without clinical or radiological sign of metastatic disease Good general status (OMS ≤ 2) Patient able to ingest food. Age ≥ 18 years Wellinformed written consent, signed by the patient. Patient with sickness benefit Patient with relapse ever treated by radiotherapy Other prospective study's participation Recent and massive digestive haemorrhage Medical contraindication like main general status alteration, uncontrolled serious infectious disease, main uncontrolled metabolic anomaly ongoing. Preexistent pulmonary pathology (BPCO, pleurisy, lymphangitis, interstitial syndrome) Severe cardiac pathology (stage 3 or 4 cardiac insufficiency, unstable angina pectoris, uncontrolled arrhythmia, myocardium's infarction antecedent during the year that precede the inclusion. Ophthalmic pathology antecedent concerning the ocular surface or lenscarrier Concomitant administration, by local or general tract, of drug responsible for ocular drought or which could delay the epithelial cicatrization Less than 1000 polynuclear neutrophil leucocytes or less than 75000 bloodplatelets at inclusion Bilirubin at higher concentration than one point five times the normal Renal insufficiency (glomerular filtration flow ≤ 40 ml/min)calculated in accordance with Cockroft's formula Tacking of Beta blockers, amiodarone, NSAIDs, bleomycin, just before or during the study Pregnant or nursing women Patient under guardianship or trusteeship.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Head and Neck Neoplasms</keyword>
	<keyword>Tarceva</keyword>
	<keyword>ENT</keyword>
</DOC>